newsfilter
← Latest News
GlobeNewswire·

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

  • XORTX Therapeutics Inc. extended its acquisition agreement with Vectus Biosystems Limited to close on or before March 31, 2026, to allow more time for intellectual property transfer.
  • The original term sheet required closing within 90 days of execution but is now subject to final documentation, regulatory approvals, & stock exchange compliance.
  • The acquisition involves the Renal Anti-Fibrotic Therapeutic Program, including the novel chemical entity VB4-P5 & its associated IP & manufacturing data.
  • XORTX scheduled its Annual & Special Meeting of Shareholders for Tuesday, March 24, 2026, with a record date of February 20, 2026.
  • New board member Krysta Davies Foss received 20,000 stock options exercisable at CAD $0.69 for a five-year period.
  • VB4-P5 is a small molecule showing potential to inhibit or reverse kidney fibrosis, with patent protection in over 30 jurisdictions.
  • XORTX has three clinically advanced programs (XRx-026 for gout, XRx-008 for ADPKD, XRx-101 for acute organ injury) & one pre-clinical program (XRx-225 for Type 2 diabetic nephropathy).
  • The press release includes forward-looking statements regarding financing, clinical trial success, & intellectual property protection that may differ from actual results.